Committee for Advanced Therapies
Generated by GPT-5-miniExpansion Funnel Raw 66 → Dedup 0 → NER 0 → Enqueued 0
| Committee for Advanced Therapies | |
|---|---|
| Name | Committee for Advanced Therapies |
| Abbreviation | CAT |
| Established | 2009 |
| Parent | European Medicines Agency |
| Jurisdiction | European Union |
| Headquarters | Amsterdam |
| Members | multidisciplinary experts |
Committee for Advanced Therapies
The Committee for Advanced Therapies is a scientific committee within the European Medicines Agency advising on scientific, regulatory and technical issues related to advanced therapy medicinal products, including gene therapy, somatic cell therapy, and tissue-engineered products. It issues scientific recommendations that inform centralized marketing authorizations, interacts with national competent authorities such as the Medicines and Healthcare products Regulatory Agency and the Agence nationale de sécurité du médicament et des produits de santé, and supports policy development by institutions like the European Commission and the European Parliament. The committee’s opinions shape interactions among stakeholders including pharmaceutical industry, biotechnology companies, academic centers such as Karolinska Institutet and University of Oxford, and patient organizations like the European Patients' Forum.
Overview
Established as part of the regulatory architecture of the European Medicines Agency in 2009, the Committee for Advanced Therapies brings together experts from member states represented by agencies such as the Paul-Ehrlich-Institut and the Istituto Superiore di Sanità. It operates within the framework of Regulation (EC) No 1394/2007 adopted by the European Parliament and the Council of the European Union, aligning with guidance from bodies such as the World Health Organization and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The committee’s remit intersects with stakeholders spanning European Commission Directorate-General for Health and Food Safety, regional regulators like the Bundesinstitut für Arzneimittel und Medizinprodukte, research funders such as the European Research Council, and major clinical centers including Mayo Clinic and Karolinska University Hospital.
Role and Responsibilities
The committee provides scientific recommendations to the European Medicines Agency on classification, certification, and marketing authorization of advanced therapy medicinal products, liaising with national agencies such as the Swedish Medical Products Agency and the Spanish Agency of Medicines and Medical Devices. It offers scientific advice used by applicants from Novartis and Gilead Sciences to Oxford Biomedica and university spin-outs, and issues scientific opinions that inform European Commission decisions, regulatory pathways used in jurisdictions like the United States Food and Drug Administration and the Japanese Pharmaceuticals and Medical Devices Agency, and reimbursement deliberations involving entities such as the European Investment Bank or national health services like the National Health Service (England).
Regulatory Procedures and Guideline Development
The committee develops guidelines and contributes to regulatory procedures including classification requests, orphan designation interactions with the European Medicines Agency Committee for Orphan Medicinal Products, and certification of quality and non-clinical data for small and medium-sized enterprises and academic sponsors. It integrates scientific methodologies from institutions like European Centre for Disease Prevention and Control and aligns with standards from the International Organization for Standardization and the Clinical Trials Directive transitions to the Clinical Trials Regulation (EU) No 536/2014. CAT outputs inform marketing authorization dossiers submitted by companies such as UniQure and Bluebird Bio, and influence post-authorization safety monitoring coordinated with the Pharmacovigilance Risk Assessment Committee.
Scientific Committees and Working Groups
The committee collaborates with other scientific committees and working groups within the European Medicines Agency, including the Pharmacovigilance Risk Assessment Committee, the Committee for Medicinal Products for Human Use, and task forces involving the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. It convenes expert subgroups comprising specialists from academic institutions such as University College London, translational research centers like Cleveland Clinic, and experts associated with consortia such as ERINHA or IMI. Ad hoc working groups address technical topics—manufacturing, comparability, potency assays—drawing expertise paralleling that of European Directorate for the Quality of Medicines and national laboratories.
Notable Opinions and Impact on Advanced Therapy Medicinal Products
The committee’s scientific opinions have directly influenced authorization trajectories for high-profile products developed by companies such as Novartis (e.g., CAR-T therapies) and Spark Therapeutics, and informed regulatory stances affecting clinical programs at Imperial College London and Karolinska Institutet. Its classification decisions have clarified distinctions between gene-modified and non-modified cell therapies, impacting regulatory strategies used by sponsors including Moderna affiliates and Pfizer collaborations. CAT opinions have also shaped policy debates in the European Parliament on access, pricing, and cross-border healthcare involving entities like the Council of the European Union and national payers.
Interaction with National Agencies and Stakeholders
CAT maintains formal and informal channels with national competent authorities such as the Italian Medicines Agency, industry associations including European Federation of Pharmaceutical Industries and Associations, patient groups like European Cancer Organisation, and research networks exemplified by European Molecular Biology Laboratory. It participates in scientific advice meetings with applicants from startups incubated by Cambridge Enterprise or ETH Zurich spin-offs, and supports capacity building through workshops with regulators from accession countries, international partners such as the World Bank, and clinical networks including European Reference Networks.
Criticisms and Challenges
Critiques of the committee have come from academic commentators, industry observers, and patient advocates regarding timelines, transparency, and adaptability to rapid innovation exemplified by platforms from CRISPR Therapeutics and emerging modalities pursued by Regeneron Pharmaceuticals. Challenges include harmonizing approaches across national agencies like the Hungarian National Institute of Pharmacy and Nutrition, accommodating accelerated pathways used in the United States Food and Drug Administration's breakthrough designations, and addressing complex manufacturing issues related to contract manufacturing organizations and supply chains linked to companies such as Lonza. Calls for reform cite precedents from regulatory evolution in the European Medicines Agency and collaborative models used by the International Coalition of Medicines Regulatory Authorities.